åŠåš äžæã»åŸæã«ãããèé žã®æå³
åŠåš æã®æ é€è£çµŠã«ãããŠãç¹ã«åæïŒåŠåš åïœåŠåš 12é±é ïŒã«æ³šç®ãããã®ãããã¿ãã³ Bâ矀ã®äžçš®ã§ãããèé žïŒfolic acidïŒfolateïŒããç¥çµç®¡ééé害ïŒNTD: neural tube defectsïŒäºé²ã®èгç¹ãããå€ãã®ã¬ã€ãã©ã€ã³ã§åŠåš åããã®èé žæåãæšå¥šãããŠãããããšãã°ãåŠåš åãåŠåš åæã«èé žãè£çµŠããããšã§ãNTDã®çºçãªã¹ã¯ãäœäžãããšãããšããã³ã¹ã¯ç¢ºç«ãããŠããããžã£ãŒãã«ãªãã¢ã¡ãªã«ã³ã¡ãã£ã«ã«ã¢ãœã·ãšãŒã·ã§ã³+1
ãããäžæ¹ã§ãåŠåš äžæããã³åŸæïŒããããåŠåš 13é±ä»¥éããåºç£çŽåãŸã§ïŒã«ãããèé žè£çµŠã®æå³ã»åœ¹å²ã»æé©ãªæåéã»ãªã¹ã¯ã»éºäŒåã»ä»£è¬ãšã®é¢é£ãšãã£ãç¹ã«ã€ããŠã¯ãããã€ãŸã§ããã©ãã ãããã©ã®ã¿ã€ããé©åãããšãã£ãè°è«ãé²ãã§ãããå°éçèŠç¹ããæŽçãã䟡å€ããããæ¬çš¿ã§ã¯ãéºäŒåã»ä»£è¬ã»ãšããžã§ããã£ã¯ã¹ã®èгç¹ãå«ããŠãåŠåš äžæã»åŸæã«ãããèé žã®æçŸ©ãå æ¬çã«è«ããã
èé žã®çååŠç圹å²ãšåŠåš æã®å€å
ãŸããèé žãšã¯äœãããããŠåŠåš æã«ãããŠã©ã®ãããªä»£è¬ã»åé å€åãèµ·ããããæŽçããã
èé žïŒãã¿ãã³ BâïŒãšã¯
èé žïŒfolateïŒã¯ãäœå ã«ãããŠäžççŽ ïŒC1ïŒãŠãããã鿬ã»äŸçµŠããã³ãã¡ã¯ã¿ãŒãšããŠæ©èœãããDNAã»RNAåæãã¡ãã«ååå¿ïŒãã¢ã·ã¹ãã€ã³ããã¡ããªãã³ãžã®åã¡ãã«åãS-ã¢ããã·ã«ã¡ããªãã³ïŒSAMïŒçæïŒãã¢ããé žä»£è¬ãªã©ã现èåè£ãæé·ã修埩ã«å¿ é ã®ãã¿ãã³ã§ããããŠã£ãããã£ã¢+1
èé žã®åœ¹å²ã¯ãå€å²ã«ãããããç¹ã«æ¬¡ã®ãããªæ©æ§ã泚ç®ãããŠããïŒ
- DNAå¡©åºïŒç¹ã«ãããžã³ïŒåæïŒdUMPâdTMPåå¿ã«äžççŽ åäœãé¢äžããèé žãé¢äžããããŠã£ãããã£ã¢
- ã¡ãã«ååå¿ïŒ5-ã¡ãã«ããã©ãããèé žïŒ5-MTHFïŒãä»ããã¢ã·ã¹ãã€ã³ããã¡ããªãã³ãžã®åã¡ãã«åãä¿ããã¡ããªãã³ã¯SAMãžãšå€æããããã¹ãã³ãDNAã¡ãã«åã«ãå¯äžããããžã§ãŒãžã¿ãŠã³å»çã¬ãã¥ãŒ
- 现è墿®ã»ååã»ä¿®åŸ©ïŒèå ã»èç€ã»æ¯äœçµç¹ã®å¢æ®ã掻çºãªåŠåš æã«ã¯ãèé žã®éèŠãé«ãŸãã
åŠåš äžæã»åŸæã«ãããçççå€åãšèé žéèŠã®èгç¹
åŠåš ãé²ãã«ã€ããŠãæ¯äœã»èç€ã»èå ã®ä»£è¬ã»è¡æ¶²åŸªç°ã»æ é€åæ ã¯å€åãéããã以äžãèé žã®èгç¹ããæŒãããŠããããå€åãæããã
- èç€ããã³èå æé·ã®å é åŠåš äžæä»¥éãèå ã®äœéããã³èç€ãµã€ãºã¯æ¥éã«å¢å€§ããã现è墿®ã»è¡ç®¡æ°çã»ä»£è¬æŽ»æ§ãé«ãŸãã¿ã€ãã³ã°ã§ãããèé žã«ããDNAåæã»çްèåè£æ¯æŽãããéèŠãšãªãã
- æ¯äœè¡æ¶²éã»èµ€è¡çéã®å¢å åŠåš äžæããæ¯äœè¡æŒ¿éã»èµ€è¡çéãå¢å ããéã»èé žã»ãã¿ãã³Bââãªã©é è¡ç³»æ é€çŽ ã®éèŠãäžãããèé žãèµ€è¡ç圢æã»å·šèµ€èœçæ§è²§è¡äºé²ã«é¢äžããç¹ãç¡èŠã§ããªãã
- 代è¬ã»ãã¢ã·ã¹ãã€ã³åæ ã®å€å åŠåš æã¯ãã¢ã·ã¹ãã€ã³ä»£è¬ã«é¢é£ããé µçŽ ãè£é µçŽ ã®éèŠãå¢å ããèé žã»ãã¿ãã³Bââã»Bâã»ã¡ããªãã³ä»£è¬ã»äžççŽ ä»£è¬ïŒ1-C代è¬ïŒç³»ã®æ©èœç¶æãèå çºéããã³æ¯äœã®å¥åº·ç¶æã«çŽçµããã
- ãšããžã§ããã£ã¯ã¹ãšèå ããã°ã©ãã³ã° èå çºè²æã«ã¯ãæ¯äœæ é€ç¶æ ãèå ã®ãšããžã§ããã£ãã¯ä¿®é£ŸïŒDNAã¡ãã«åããã¹ãã³ä¿®é£ŸïŒãä»ããŠå°æ¥ã®ä»£è¬ã»çŸæ£ãªã¹ã¯ã«åœ±é¿ãåãŒããšãããèå ããã°ã©ãã³ã°ã仮説ãå±ããããŠãããèé žã®ãããªã¡ãã«äŸäžæ é€çŽ ã¯ãã®èгç¹ã§ã泚ç®ãããããžã§ãŒãžã¿ãŠã³å»çã¬ãã¥ãŒ
ãã®ããã«ãåŠåš äžæã»åŸæã¯ãèé žãåã«ç¥çµç®¡ééé害äºé²ã®ããã ãã§ã¯ãªããèå æé·ã»èç€æ©èœã»ãšããžã§ããã£ã¯ã¹ã»æ¯äœä»£è¬ç¶æãšããå€é¢ç圹å²ãæã€ææããšèšãããæ¬¡ç¯ã§ã¯ãåŠåš äžæã»åŸæã«ãããèé žè£çµŠã®ãšããã³ã¹ããç¹ã«éºäŒåïŒä»£è¬ïŒèšåºã¢ãŠãã«ã 芳ç¹ããæ€èšããã
åŠåš äžæã»åŸæã«ãããèé žè£çµŠã®èšåºã»éºäŒåã»ä»£è¬ãšããã³ã¹
ãã®ã»ã¯ã·ã§ã³ã§ã¯ãåŠåš 13é±ä»¥éã«èé žãã©ã®ããã«èããããææ°ã®ç ç©¶ãããšã«æãäžããŠããã
ç¥çµç®¡ééé害ïŒNTDïŒäºé²ä»¥éã®åœ¹å²
ãŸããèé žè£çµŠãç¥çµç®¡ééé害ïŒNTDïŒäºé²ã«æ¥µããŠæå¹ã§ããããšã¯ããç¥ãããŠãããäŸãã°ã芳å¯ç ç©¶ã§ã¯ãåŠåš åãåŠåš äžã«èé žã䜿çšãã女æ§ã§ã¯ãNTDãªã¹ã¯ã®ææãªäœäžãå ±åãããŠããããžã£ãŒãã«ãªãã¢ã¡ãªã«ã³ã¡ãã£ã«ã«ã¢ãœã·ãšãŒã·ã§ã³+1
ããããåŠåš äžæä»¥éã«è£çµŠãç¶ããæçŸ©ã«é¢ããŠã¯ãæ¯èŒçæè¿ã«ãªã£ãŠè°è«ãé²ãã§ãããããã€ãã®ç ç©¶ããç¶ç¶è£çµŠã«ããåã©ãã®èªç¥çºéæ¹åãããåŠåš é«è¡å§çå矀ïŒGHDïŒãªã¹ã¯äœæžããªã©ã®å¯èœæ§ãæç€ºããŠããã
ç¶ç¶è£çµŠãšåã©ãã®èªç¥çºé
äŸãã°ãEffect of continued folic acid supplementation beyond the first trimesterïŒMcNulty H ä»ã2019幎ïŒã¯ãåŠåš åæãéããŠãèé žè£çµŠãç¶ç¶ããæ¯äœã®åã©ãã§ãèªç¥çºéã«ãããæçãªåœ±é¿ã瀺åãããïŒãã ãã©ã³ãã å詊éšã§ã¯ãªãïŒãšããŠãããBioMed Central
ãã®ãããªçµæãããç¥çµç®¡ééåŸæã«ãèé žãäœçšãåŸãèæ¯ãšããŠããèé žãéããDNAã¡ãã«åã»ç¥çµåè·¯çºéã»èå è³æé·æ¯æŽããæ³å®ãããã
åŠåš äžæã»åŸæã®æ¯äœå䜵çïŒäŸïŒåŠåš é«è¡å§ã»å眮èç€ïŒããã³èé ž
ããæè¿ã®å ±åã§ã¯ãåŠåš äžæãåŸæã®èé žè£çµŠå»¶é·ãåŠåš é«è¡å§çå矀ïŒGHDïŒãå眮èç€ãäœåºçäœéå ãªã¹ã¯äœæžãšé¢é£ããå¯èœæ§ãåºãŠããŠãããäŸãã°ãDuration of Folic Acid Supplementation and Pregnancy OutcomesïŒZhang M ä»ã2025幎ïŒã¯ããäžæãŸã§/åŸæãŸã§èé žè£çµŠãå»¶é·ããããšã¯ãåŠåš é«è¡å§ã»æªç£ç£åºå ãªã¹ã¯ãäœæžããããšãã芳å¯ããŒã¿ãå ±åããŠãããcdn.nutrition.org
ãããã®å ±åã¯èгå¯çã§ã¯ããããåŠåš äžæä»¥éã«ãããŠãèé žè£çµŠãâèç€ã»æ¯äœè¡ç®¡ã»è¡å§èª¿ç¯âã«ãé¢é£ããå¯èœæ§ã瀺ããŠããã
éºäŒåã»ä»£è¬ãããã¡ã€ã«ãšèé žè£çµŠã®çžäºäœçš
åŠåš äžæã»åŸæã®èé žè£çµŠã«ãããŠãç¹ã«è峿·±ãã®ããæ¯äœã»èå ã®éºäŒåå€ç°ã»ä»£è¬å€åããèé žè£çµŠå¹æãæé©éã«åœ±é¿ãäžãããšããç¹ã§ããã以äžãäž»èŠãªãã€ã³ããæŽçããã
MTHFRå€ç°ãšèé žè£çµŠ
代衚çãªãã®ãšããŠãMTHFRïŒã¡ãã¬ã³ããã©ãããèé žéå é µçŽ ïŒC677Tå€åãããããã®å€åãæããæ¯äœã»èå ã§ã¯ãèé žä»£è¬ãããäœå¹çãšãªãããã¢ã·ã¹ãã€ã³é«å€ãäœèé žç¶æ ã®åœ±é¿ãåãããããããããèæ¯ãããåŠåš æã®èé žè£çµŠã«ãããŠå€åãèæ ®ãã¹ããšããè°è«ãããã
å®éãããç ç©¶ã§ã¯ãåŠåš äžæïœåŸæã«ç³å°¿ç å䜵åŠåš ïŒGDM: gestational diabetes mellitusïŒãã€æ¯äœMTHFR 677 TTåãæãã矀ã§ãæšæºé400 µg/æ¥ããã800 µg/æ¥ã®èé žè£çµŠããããæ©ãååŸ©ã»æ¹åãã瀺ãããšããå ±åããããFrontiers
ãã®çµæã¯ã âåŠåš äžæã»åŸæã«ãããèé žè£çµŠæé©åâ ãæ€èšããäžã§ãéºäŒåãããã¡ã€ã«ãéèŠãªèª¿æŽå åã«ãªãå¯èœæ§ã瀺ããŠããã
äžççŽ ä»£è¬ã»ãã¢ã·ã¹ãã€ã³çµè·¯ã»èé žã®åœ±é¿
èé žãé¢äžãã1-C代è¬ïŒã¡ããªãã³/ãã¢ã·ã¹ãã€ã³ãµã€ã¯ã«ïŒã¯ãèå çºè²ã»æ¯äœä»£è¬ã»è¡ç®¡æ©èœã»ãšããžã§ããã£ãã¯å¶åŸ¡ãšå¯æ¥ã«é¢é£ããããã®çµè·¯ãããŸãæ©èœããªããšãæ¯äœãã¢ã·ã¹ãã€ã³äžæãDNAã¡ãã«åç°åžžãèç€è¡ç®¡æ©èœäœäžãªã©ãéããŠãèå çºè²å¶éïŒFGRïŒãæ©ç£ãåŠåš é«è¡å§çå矀ãªã©ã®ãªã¹ã¯ãé«ãŸããšãã仮説ãããã
èé žè£çµŠã«ããããã¢ã·ã¹ãã€ã³äœäžãã¡ããªãã³ã»SAMå¢å ãDNAã¡ãã«åæ£åžžåãšããäžé£ã®æ¹åãèµ·ããå¯èœæ§ããããåŠåš äžæã»åŸæã®ãããã代è¬è£å©ã®åœ¹å²ã泚ç®ãããŠãããããšãã°ãèç€è¡ç®¡æ°çã现èåè£ãçããªãã®ææã§ã¯ãèé žãâæ¯äœïŒèç€ïŒèå âéã®ä»£è¬é£é¢ãæ¯ãããšããèŠç¹ãæãç«ã€ã
ãšããžã§ããã£ã¯ã¹ã»èå ããã°ã©ãã³ã°ã®èгç¹
è¿å¹Žãèå æã®æ é€ïŒç¹ã«ã¡ãã«äŸäžæ é€çŽ ïŒãšå°æ¥ã®ä»£è¬ã»çŸæ£ãªã¹ã¯ãšã®é¢é£ã瀺ããèå ããã°ã©ãã³ã°ãç ç©¶ãå¢ããŠããŠãããèé žãå«ãã¡ãã«äŸäžæ é€çŽ ã¯ãèå ã®DNAã¡ãã«åãã¿ãŒã³ããã¹ãã³ä¿®é£ŸãmiRNAçºçŸãªã©ã«äœçšããåºçåŸã»æäººæã®è¥æºã»ç³ä»£è¬ç°åžžã»è¡ç®¡çŸæ£ãªã¹ã¯ã«åœ±é¿ãäžããå¯èœæ§ããããšããå ±åãããããžã§ãŒãžã¿ãŠã³å»çã¬ãã¥ãŒ
åŠåš äžæã»åŸæã¯ãèå åšå®ã®åŸ®èª¿æŽæãè¡ç®¡ã»ä»£è¬ç³»ã®å®ææãšãèšãããããèé žè£çµŠããçºè²å®äºã«åãã埮修æ£ããæ ãããšããä»®èª¬ãæ¯æãããŠããã
åŠåš äžæã»åŸæã«ãããèé žè£çµŠã®èšåºè©Šéšã»èгå¯ç ç©¶ã®èŠç¹
以äžãåŠåš äžæã»åŸæã«å¶é žãè£çµŠããå Žåã®èšåºã»èгå¯ç ç©¶ããåŸãããäž»ãªç¥èŠãæŽçããã
- ç¶ç¶è£çµŠãšèå æé·ïŒ2016幎ã«çºè¡šããã芳å¯ç ç©¶ïŒMaternal Continuing Folic Acid Supplementation after the 12th Week of GestationïŒã§ã¯ãåŠåš 12é±ä»¥éãèé žè£çµŠãç¶ç¶ããæ¯äœã§ã¯åºçäœéããããã«é«ããäœåºçäœéå ãªã¹ã¯ãäœãã£ããšããå ±åããããMDPI
- åŠåš é«è¡å§ã»å眮èç€ã»èç€æ©èœïŒåé ã«è§ŠããZhangãïŒ2025幎ïŒã®å ±åã§ã¯ãèé žè£çµŠæéãäžæã»åŸæãŸã§å»¶é·ããããšã§ãåŠåš é«è¡å§çå矀ã»å眮èç€ã»ãã®ä»æªç£ç£åºå ã®ãªã¹ã¯äœæžãšããé¢é£ã芳å¯ããããcdn.nutrition.org
- çŸæ£ååŸ©ã»æ¯äœä»£è¬æ¹åïŒGDMçïŒïŒåè¿°ã®ç ç©¶ã§ã¯ãåŠåš äžæä»¥éã®é«çšéèé žïŒ800 µg/æ¥ïŒãGDMå䜵åŠåš ã»MTHFR 677 TT忝äœã«ãããŠãæšæºé400 µg/æ¥ããæ©æå埩ã瀺ãããFrontiers
- å®å šæ§ã»éå°æåãªã¹ã¯ïŒãšã¯ãããèé žãäžæã»åŸæã«é«çšéã»é·æã«ããã£ãŠè£çµŠããããšã®å®å šæ§ã«ã€ããŠã¯æ éè«ãããã2025幎ã®ã¬ãã¥ãŒïŒLedowsky C ä»ïŒã§ã¯ããéå°ãªèé žè£çµŠããã³é«èé žè¡çããç¥çµçºéã»ä»£è¬ç°åžžãšé¢é£ããå¯èœæ§ãã瀺åãããŠããã驿£ãªéã»ã¿ã€ãã³ã°ã»éºäŒåèæ¯ãèæ ®ãã¹ããšãããŠããããµã€ãšã³ã¹ãã€ã¬ã¯ã
ããããç·åãããšãåŠåš äžæã»åŸæã«ãããèé žè£çµŠã¯ãå¯èœæ§ãšããŠå€ãã®ã¡ãªãããæã€ããå奿é©åãéèŠãã§ãããâäžåŸéã»äžåŸææâã§ã¯ãªããæ¯äœéºäŒåã»ä»£è¬ãããã¡ã€ã«ã»å䜵çãªã¹ã¯ã»æ é€ç¶æ ãèžãŸããæŠç¥çè£çµŠãæ±ããããã
åŠåš äžæã»åŸæèé žè£çµŠã®å®çšçã¬ã€ãã©ã€ã³ïŒå°éå®¶åãèŠç¹ïŒ
ãã®ã»ã¯ã·ã§ã³ã§ã¯ãå°éå®¶ïŒéºäŒåæ€æ»æ åœè ãç£ç§æ é€å£«ãéºäŒã«ãŠã³ã»ã©ãŒçïŒåãã«ãåŠåš äžæã»åŸæã®èé žè£çµŠãèšèšã»å®æœããããã®èãæ¹ããã§ãã¯ãã€ã³ããéºäŒåæ€æ»ãšã®é£æºãå®éã®åŠæ¹ã»ã¢ãã¿ãªã³ã°æ¹æ³ãæŽçããã
1. 察象ãšãªãæ¯äœïŒåŠå©Šãæ³å®ããå±€å¥å
èé žè£çµŠæŠç¥ãçå®ããã«ã¯ããŸãè£çµŠãå»¶é·ã»å¢éããé©åãªå±€ãšãæšæºéç¶ç¶ã§ããå±€ãèå¥ããããšãéèŠã§ããã以äžãå°ãªããšãæ€èšãã¹ãæ¯äœãªã¹ã¯ã»éºäŒåèæ¯ãåæããïŒ
- éºäŒåå€ç°ä¿æãªã¹ã¯ïŒMTHFR C677TïŒA1298Cãå€åã«ããèé žä»£è¬äœäžã»ãã¢ã·ã¹ãã€ã³äžæåŸåããã
- æ¯äœå䜵çãªã¹ã¯ïŒåŠåš é«è¡å§çåçŸ€ã®æ¢åŸã»å®¶ææŽãèç€æ©èœäœäžã»å眮èç€ã»çŸæ°Žç°åžžã»èå çºè²å¶éïŒFGRïŒãªã¹ã¯ã
- æ é€ç¶æ ã»è¡æ¶²æ€æ»ïŒèé žè¡äžæ¿åºŠã»èµ€è¡çèé žã»ãã¢ã·ã¹ãã€ã³ã»ãã¿ãã³ Bââã»éç¶æ ã»è²§è¡ç¶æ³ã
- åŠåš äžæä»¥éã«çºçã»ç¶ç¶äžã®çç¶ïŒGDMïŒåŠåš ç³å°¿ç ïŒãåŠåš è²§è¡ãæ¯äœè æ©èœã»èæ©èœç°åžžã
- åŠåš åæïŒïœ12é±ïŒã«èé žãååã«æåããŠãããåŠãã
ãããã®èŠå ãããšã«ãåŠåš 13é±ä»¥éãèé žè£çµŠãç¶ç¶ïŒå¢éïŒæšæºç¶ç¶ãã®ã©ããé©åããæ€èšããã
2. è£çµŠéã»ã¿ã€ãã³ã°ã®ç®å®ïŒäžæã»åŸæïŒ
å°éå®¶åãã«ã¯ã次ã®ãããªç®å®ãæç€ºã§ããããåå¥ã«éºäŒåã»ä»£è¬ãããã¡ã€ã«ãåæ ããŠæçµå€æãã¹ãã§ããïŒ
- æšæºç¶ç¶ïŒå€ãã®åŠå©Šã«ãããŠãåŠåš åæã«æ¡çšãããèé žéïŒããšãã°400 µg/æ¥ïŒãäžæä»¥éãç¶ç¶ãããŠããã°ãç¹æ®µã®ãªã¹ã¯å åããªãéããŸã劥åœãšèããããã
- å¢éïŒå»¶é·ïŒæ¬¡ã®ãããªã±ãŒã¹ã§ã¯ãåŠåš äžæã»åŸæã«èé žéãå¢ããïŒäŸïŒ400 µg â 800 µg/æ¥ïŒãæ€èšãããïŒ
- MTHFRå€åä¿æïŒç¹ã«677 TTåïŒïŒä»£è¬ç°åžžã»ãã¢ã·ã¹ãã€ã³äžæåŸåããã
- åŠåš é«è¡å§çå矀ã»GDMã»èç€ç°åžžã»èå çºè²å¶éãªã©ã®ãªã¹ã¯ã»æ¢åŸããã
- åŠåš åæã®èé žæåãäžååã ã£ãããŸãã¯æ é€ç¶æ ã«æžå¿µããã
- ã¢ãã¿ãªã³ã°ä»ã調æŽïŒå¢éãæ€èšããå Žåã¯ã以äžã®ã¢ãã¿ãªã³ã°ãè¡ãã¹ãã§ããïŒ
- åŠåš 20é±ã»28é±ã»36é±ãããã§ãã¢ã·ã¹ãã€ã³ã»èé žïŒè¡äžã»èµ€è¡çïŒã»ãã¿ãã³ Bââãæž¬å®ã
- åŠåš äžæã»åŸæã®æ¯äœè¡å§ã»èç€è¡æµïŒãšã³ãŒïŒã»èå çºè²ïŒè¶ 鳿³¢ïŒã宿è©äŸ¡ã
- èé žéå°ïŒç¹ã«æªä»£è¬èé žïŒUMFAïŒãé¿ãã芳ç¹ãããâ驿£äžéâãæèãéå°èé žã«ã¯é·æçãªä»£è¬ã»ç¥çµçºéã«é¢ããæžå¿µå ±åããããµã€ãšã³ã¹ãã€ã¬ã¯ã
3. éºäŒåæ€æ»ã»ä»£è¬æ€æ»ãšã®é£æº
éºäŒåã»ä»£è¬ãããã¡ã€ã«ã掻çšããŠèé žè£çµŠèšèšãé«åºŠåããããã«ã¯ã以äžã®ããã»ã¹ãèããããã
- éºäŒåæ€æ»ïŒæ¯äœïŒããã³å¯èœã§ããã°èå ïŒç¶äœïŒã«ãããŠãMTHFR C677Tã»A1298CãMTRRãDHFRãSHMTãªã©äžççŽ ä»£è¬é¢é£å€åãæ€æ»ãããã«ãããèé žä»£è¬å¹çãããã¢ã·ã¹ãã€ã³ä»£è¬ãªã¹ã¯ããã¡ãã«åè² è·ç¶æ ãã®äºåè©äŸ¡ãå¯èœã
- 代è¬ããŒã«ãŒæž¬å®ïŒèé žïŒè¡æž ã»èµ€è¡çïŒããã¢ã·ã¹ãã€ã³ãã¡ããªãã³ãSAM/SAHæ¯ïŒå¯èœãªæœèšã§ã¯ïŒãäžæã»åŸæã«æž¬å®ããããã®å€ãããèé žè£çµŠã代è¬çã«å¹æãåºããŠãããããè£çµŠéãå¢ãå¿ èŠãããããã倿ã§ããã
- æ é€ã»é£äºèæ¯è©äŸ¡ïŒèé žè±å¯é£åïŒç·é»è²éèãè±é¡ã匷åç©ç©ïŒããä»ã®ã¡ãã«äŸäžæ é€çŽ ïŒãã¿ãã³ BââãBâããã¿ã€ã³ããã¢ã·ã¹ãã€ã³ä»£è¬è£å åïŒã®æåç¶æ³ã確èªãããããäžè¶³ããŠããå Žåãèé žè£çµŠåç¬ã§ã¯ä»£è¬è£å¡«ãäžååãšãªãããã
- ç¶ç¶çãã©ããŒïŒæ€æ»çµæãšæ¯äœã»èå çµéïŒçºè²ã»å䜵ççºçŸïŒãã¢ãã¿ãªã³ã°ããå¿ èŠã«å¿ããŠèé žéã»ã¿ã€ãïŒ5-MTHFãªã©ïŒã調æŽãããšãã°ãèé žä»£è¬é害ã®å€åã確èªãããå Žåã5-ã¡ãã«ããã©ãããèé žïŒ5-MTHFïŒãžã®åãæ¿ãæ€èšãããããžã§ãŒãžã¿ãŠã³å»çã¬ãã¥ãŒ
4. èé žã¿ã€ãã»è£çµŠåœ¢åŒã®æ€èš
èé žã«ã¯ãåæãããèé žïŒfolic acidïŒããšã掻æ§åèé žïŒ5-MTHFãªã©ïŒãããããåŠåš æãç¹ã«ä»£è¬äœå¹çã®æ¯äœã§ã¯æŽ»æ§åã®äœ¿çšãæ€èšãããŠããã
- åæèé žïŒfolic acidïŒã¯äœå ã§éå ã»ã¡ãã«åãããŠ5-MTHFã«ãªãéçšãèŠãããããé µçŽ æŽ»æ§äœäžåïŒããšãã°MTHFRå€åïŒã§ã¯ååæŽ»æ§åãããªãå¯èœæ§ããã
- ãã®ãããæŽ»æ§åèé žïŒ5-MTHFïŒè£çµŠã代æ¿ã»äœµçšãšããŠæ³šç®ãããŠãããç¹ã«å€åä¿æã®åŠå©Šã»ãã¢ã·ã¹ãã€ã³é«å€ã®æ¯äœã§ã¯æ€èšäŸ¡å€ãããããžã§ãŒãžã¿ãŠã³å»çã¬ãã¥ãŒ
- è£çµŠåœ¢åŒãšããŠã¯ãéåžžã®çµå£ãµããªã¡ã³ããŸãã¯åŒ·åé£ååãšãšãã«ãé£äºé¢ããã®èé žæå匷åïŒç·èéèãè±é¡ãã¬ããŒã匷åç©ç©ïŒã䞊è¡ããŠè¡ãããšã§ãç·æåéã»ãã€ãªã¢ãã€ã©ããªãã£ïŒçç©åŠçå©çšèœïŒãæ¹åã§ããã
5. ãªã¹ã¯ãšçæç¹ïŒéå°æåã»æªä»£è¬èé žïŒUMFAïŒã»é·æéè£çµŠ
èé žè£çµŠãèšèšããéã«ã¯ãç¹ã«åŠåš äžæã»åŸæã®é·æã»é«çšéè£çµŠã«é¢ããŠæ¬¡ã®ãªã¹ã¯ã»æ³šæç¹ãèæ ®ããå¿ èŠãããã
- æªä»£è¬èé žïŒUMFAïŒèç©ïŒé«çšéèé žãç¶ç¶æåããããšã§ãäœå ã«éå ã»ã¡ãã«åã§ããã«æ®åãããæªä»£è¬èé žïŒUMFAïŒããè¡äžã«æ€åºãããããšããããæè¿ã®ç ç©¶ã§ãã®èç©ãç¥çµçºéã»ä»£è¬ç³»ã«äžãã圱é¿ãæ€èšãããŠãããPubMed+1
- é«èé žè¡çã»ä»£è¬ç°åžžãšã®é¢é£ïŒã¬ãã¥ãŒã§ã¯ãéå°èé žããã³é«èé žè¡çãç¥çµçºéïŒèªéã¹ãã¯ãã©ã é害ïŒã代è¬ç°åžžïŒç³ä»£è¬é害ïŒãšé¢é£ããå¯èœæ§ã瀺åãããŠãããç¹ã«åŠåš äžæã»åŸæã«ãããé«çšéã»é·æäœ¿çšã«ã¯æ éãªæ€èšãå¿ èŠãšãããŠããããµã€ãšã³ã¹ãã€ã¬ã¯ã
éºäŒåæ€æ»ïŒèé žè£çµŠãåãå ¥ããèšèšäºäŸïŒã·ããªãªïŒ
ããã§ã¯ãéºäŒåã»ä»£è¬ãããã¡ã€ã«ãçšããŠãåŠåš äžæã»åŸæã®èé žè£çµŠæŠç¥ãèšèšããâæš¡æ¬ã·ããªãªâãæç€ºããïŒå°éå®¶çšïŒã
ã·ããªãª AïŒãªã¹ã¯äœãã®äžè¬åŠå©ŠïŒéºäŒåå€ç°ãªãïŒè¯å¥œãªæ é€ç¶æ ïŒ
- æ¯äœïŒ30æ³ãèªç¶åŠåš ãåŠåš 12é±çµäºãèé ž400 µg/æ¥ïŒé£äºã§èé žæåé 調ãMTHFR C677TïŒA1298CãšãéçåïŒCCïŒAAïŒããã¢ã·ã¹ãã€ã³æ£åžžç¯å²ã
- æŠç¥ïŒåŠåš 13é±ãããèé ž400 µg/æ¥ãç¶ç¶ãèé žè±å¯é£åïŒã»ãããèãæè±ãã¬ã³ãºè±ïŒãæèãåŠåš 20é±ã»28é±ã»36é±ã§ãã¢ã·ã¹ãã€ã³ã»èµ€è¡çèé žãã¢ãã¿ãªã³ã°ãç¹æ®µã®ç°åžžãªå€åãªããã°ãåéç¶ç¶ãšããã
- éºäŒåã»ä»£è¬çã«ãªã¹ã¯ãäœããããå¢éãåãæ¿ãã¯è¡ããããŸãã¯ãé£äºïŒæšæºè£çµŠãã®æŠç¥ã§ååãšå€æã
ã·ããªãª BïŒMTHFR 677 TTåïŒåŠåš é«è¡å§ãªã¹ã¯ãã
- æ¯äœïŒ35æ³ãèªç¶åŠåš ãåŠåš 12é±çµäºãèé ž400 µg/æ¥éå§ãéºäŒåæ€æ»ã§MTHFR C677T TTåã確èªãåŠåš 忢åŸã§è»œåºŠã®é«è¡å§ãããåŠåš 13é±ä»¥éãè¡å§äžæåŸåããã
- æŠç¥ïŒ
- ãŸããèé žã400 µg/æ¥ãã800 µg/æ¥ãžå¢éïŒåŠåš äžæä»¥éïŒãæ€èšã
- åæã«ã5-MTHFïŒæŽ»æ§åèé žïŒãžã®åãæ¿ããæ€èšã
- åŠåš 20é±ã»28é±ã»36é±ã§ãã¢ã·ã¹ãã€ã³ã»èµ€è¡çèé žã»UMFAãæž¬å®ãèç€è¡æµãšã³ãŒã»èå äœéè©äŸ¡ã䜵è¡ã
- æ é€é¢ã§ã¯ãèé žä»¥å€ã®ã¡ãã«äŸäžæ é€çŽ ïŒãã¿ãã³ BââãBâããã¿ã€ã³ïŒã匷åã
- èç€æ©èœäœäžã»çºè²å¶éåŸåãããå Žåã«ã¯ãèé žè£çµŠã«å ããŠæ¯äœè¡ç®¡æ©èœæ¹åïŒé©åãªéåã»æ é€ïŒã䜵çšã
- çµæã¢ãã¿ãªã³ã°ã§ãããã¢ã·ã¹ãã€ã³äœäžïŒèå çºè²æ£åžžïŒæ¯äœè¡å§å®å®ãã確èªã§ãããã800 µg/æ¥ã§ç¶ç¶ãéã«UMFAäžæã»ä»£è¬ããŒã«ãŒç°åžžã»èå çºè²ç°åžžãªã©ãåºãå Žåã¯ãèé žéãå ã«æ»ããå¥ã¿ã€ãã«åãæ¿ããïŒäŸïŒ5-MTHF 400-600 µgïŒæ€èšã
ã·ããªãª CïŒåŠåš ç³å°¿ç ïŒGDMïŒåäœµïŒæ 逿¬ ä¹åŸå
- æ¯äœïŒ32æ³ãåŠåš 15鱿ç¹ã§GDM蚺æãèé žéå§ãåŠåš 8é±ãã400 µg/æ¥ã ã£ããé£äºæåãååã§ãªããæ é€ç¶æ ã«äžå®ãããéºäŒåæ€æ»ã§MTHFR C677T CTåã
- æŠç¥ïŒ
- èé žã400 µg/æ¥ãã800 µg/æ¥ã«å¢éããããã«èé žè±å¯é£ïŒåŒ·åç©ç©ã䜵çšã
- åŠåš 16é±ïœ28é±ã«ãããŠããã¢ã·ã¹ãã€ã³ã»èµ€è¡çèé žã»èå äœéå¢å ã4-6é±éããšã«ãã§ãã¯ã
- GDM管çãšäœµè¡ããŠãèé žä»¥å€ã®ã¡ãã«æ é€çŽ ïŒBââããã¿ã€ã³ïŒãè£åŒ·ã
- æ é€ã«ãŠã³ã»ãªã³ã°ã§ãµããªã«é Œãããé£åç±æ¥èé žïŒå šäœçãªæ é€ãã©ã³ã¹æ¹åãéèŠã
- 36鱿ç¹ã§UMFA枬å®ãæ€èšããéå°è£çµŠææšãããã°èé žéã600 µg/æ¥çšåºŠã«èª¿æŽã
以äžã®ããã«ãéºäŒåã»ä»£è¬ãããã¡ã€ã«ïŒå䜵çãªã¹ã¯ïŒæ é€ç¶æ ãçµ±åããŠèé žè£çµŠèšèšãè¡ãããšã§ãåŠåš äžæã»åŸæã«ãããèé žã®æå³ãæå€§åã§ãããæ¬¡ç¯ã§ã¯ãå®åäžã®ããã§ãã¯ãªã¹ãããšããããã質åïŒFAQïŒããæç€ºããã
ãŸãšã
åŠåš äžæã»åŸæã«ãããèé žã¯ãåæã®ç¥çµç®¡ééé害äºé²ãè¶ ããèç€æ©èœç¶æã»èå çºè²ã»æ¯äœä»£è¬å®å®ã»ãšããžã§ããã£ã¯ã¹å¶åŸ¡ã«é¢ããéèŠãªæ é€çŽ ã§ãããäžæä»¥éã¯èå ãšèç€ã®æé·ãå éããèé žãä»ããDNAåæã»ã¡ãã«ååå¿ã»ãã¢ã·ã¹ãã€ã³ä»£è¬ã掻çºåãããè¿å¹Žã®ç ç©¶ã§ã¯ãèé žè£çµŠç¶ç¶ãåŠåš é«è¡å§ãäœåºçäœéå ã®ãªã¹ã¯ãæžãããåã©ãã®èªç¥çºéãæ¯ããå¯èœæ§ãå ±åãããŠãããäžæ¹ã§ãMTHFRå€åãªã©ã®éºäŒèŠå ã«ãã代è¬å¹çãç°ãªããããåå¥åãããèé žæŠç¥ïŒçšéã»è£çµŠæéã»æŽ»æ§å5-MTHFå©çšïŒãéµãšãªããéå°æåã«ããæªä»£è¬èé žïŒUMFAïŒèç©ãžã®é æ ®ãå¿ èŠã§ãããéºäŒåã»ä»£è¬ããŒã¿ã«åºã¥ãæé©èšèšããæ¬¡äžä»£ã®æ¯åã±ã¢ã®åºç€ãšãªãã